Price
$0.06
Increased by +10.28%
Dollar volume (20D)
2.92 K
ADR%
11.10
Earnings report date
Feb 28, 2024
Shares float
41.37 M
Shares short
2.00 M [4.84%]
Shares outstanding
44.57 M
Market cap
3.53 M
Beta
0.99
Price/earnings
N/A
20D range
0.05 0.07
50D range
0.05 0.09
200D range
0.05 0.21

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections.

Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia.

The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11.

In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1.

The company was founded in 2003 and is headquartered in Los Gatos, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Feb 28, 24 0.00
Increased by +100.00%
-0.02
Increased by +100.00%
Nov 3, 23 -0.00
Increased by +99.53%
-0.10
Increased by +97.80%
Sep 14, 23 -0.60
Decreased by -33.33%
-0.41
Decreased by -46.34%
May 22, 23 -0.60
Increased by +34.78%
-0.41
Decreased by -46.34%
Mar 31, 23 -0.40
Increased by +56.52%
-0.41
Increased by +2.44%
Nov 21, 22 -0.47
Increased by +75.77%
-0.17
Decreased by -176.47%
Aug 16, 22 -0.45
Increased by +18.18%
-0.06
Decreased by -650.00%
Apr 1, 22 -0.92
Decreased by -19.48%
-0.41
Decreased by -124.39%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 417.00 K
Increased by +N/A%
-83.00 K
Increased by +99.08%
Decreased by -19.90%
Decreased by N/A%
Jun 30, 23 19.65 M
Increased by +6.63 K%
12.14 M
Increased by +247.72%
Increased by +61.81%
Increased by +102.20%
Mar 31, 23 0.00
Decreased by -100.00%
-5.35 M
Increased by +47.65%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by -100.00%
-6.39 M
Increased by +37.55%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by -100.00%
-9.07 M
Increased by +56.83%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 292.00 K
Increased by +784.85%
-8.22 M
Decreased by -49.74%
Decreased by -2.82 K%
Increased by +83.08%
Mar 31, 22 570.00 K
Increased by +8.04 K%
-10.23 M
Decreased by -48.41%
Decreased by -1.79 K%
Increased by +98.18%
Dec 31, 21 570.00 K
Increased by +N/A%
-10.23 M
Decreased by -75.63%
Decreased by -1.79 K%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY